Cargando…

Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer

Men treated with androgen deprivation therapy for rising PSA after failed local therapy will often develop castrate resistance, and the appearance of metastases predicts a poor prognosis. Thus, researchers have long sought to prolong the onset of metastasis in patients with nonmetastatic castration-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crawford, E David, Stanton, Whitney, Mandair, Divneet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7367726/ https://www.ncbi.nlm.nih.gov/pubmed/32765070 http://dx.doi.org/10.2147/CMAR.S227583

Ejemplares similares

Darolutamide for prostate cancer
Publicado: (2020)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
por: Scott, Lesley J.
Publicado: (2020)

Correction to: Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer
por: Lee, Arnold
Publicado: (2023)

Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models
por: Sugawara, Tatsuo, et al.
Publicado: (2019)

Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer
por: Appukkuttan, Sreevalsa, et al.
Publicado: (2021)

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
por: Scott, Lesley J.
Publicado: (2022)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Biological insights and novel biomarker discovery through deep learning approaches in breast cancer histopathology
por: Mandair, Divneet, et al.
Publicado: (2023)

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
por: Uemura, Hiroji, et al.
Publicado: (2020)

Drug–Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer
por: Sutaria, Dhruvitkumar S., et al.
Publicado: (2022)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison
por: Chowdhury, Simon, et al.
Publicado: (2021)

Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Mori, Keiichiro, et al.
Publicado: (2020)

A Case of Persistent Low Back Pain in a Young Female Caused by a Trauma-Induced Schmorl’s Node in the Lumbar Spine Five Vertebra
por: Mohty, Kurt M, et al.
Publicado: (2017)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients
por: Lallous, Nada, et al.
Publicado: (2021)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models
por: Hammer, Stefanie, et al.
Publicado: (2021)

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
por: Gillessen, Silke, et al.
Publicado: (2023)

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies
por: Zurth, Christian, et al.
Publicado: (2019)

Selective Sensing of Darolutamide and Thalidomide in Pharmaceutical Preparations and in Spiked Biofluids
por: Talaat, Wael, et al.
Publicado: (2022)

Prediction of incident myocardial infarction using machine learning applied to harmonized electronic health record data
por: Mandair, Divneet, et al.
Publicado: (2020)

Darolutamide antagonizes androgen signaling by blocking enhancer and super‐enhancer activation
por: Baumgart, Simon J., et al.
Publicado: (2020)

Comparative Proteomic and Transcriptomic Analysis of the Impact of Androgen Stimulation and Darolutamide Inhibition
por: Nevedomskaya, Ekaterina, et al.
Publicado: (2022)

Clinical Pharmacokinetics and Pharmacodynamics of the Next Generation Androgen Receptor Inhibitor—Darolutamide
por: Podgoršek, Eva, et al.
Publicado: (2023)

ARASENS Trial: Should darolutamide now be added to androgen-deprivation therapy and docetaxel in patients with metastatic, hormone-sensitive prostate cancer?
por: Kumar, Naveen
Publicado: (2022)

The treatment of female stress urinary incontinence: an evidenced-based review
por: Cameron, Anne P, et al.
Publicado: (2011)

Efficacy of implementation strategies of an evidenced-based awakening and breathing protocol
por: Almuslim, O, et al.
Publicado: (2011)

Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells
por: Gupta, Siddharth, et al.
Publicado: (2020)

Evidenced-Based Claims About Evidence
por: Howard, David H.
Publicado: (2017)

Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2017)

YIV-818-A: a novel therapeutic agent in prostate cancer management through androgen receptor downregulation, glucocorticoid receptor inhibition, epigenetic regulation, and enhancement of apalutamide, darolutamide, and enzalutamide efficacy
por: Lam, Wing, et al.
Publicado: (2023)

Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment
por: Zurth, Christian, et al.
Publicado: (2021)

Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Wenzel, Mike, et al.
Publicado: (2021)

Pulmonary rehabilitation: A regional perspective evidenced-based review
por: Al Moamary, Mohamed S., et al.
Publicado: (2014)

Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Wenzel, Mike, et al.
Publicado: (2023)

Utility of green chemistry for native spectrofluorimetric quantification of darolutamide as a modern anti-neoplastic drug in its market form and biological fluids
por: Salem, Hesham, et al.
Publicado: (2022)

Pandemic triage: clipboard medicine or evidenced based?
por: Guest, T, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_cdadjonrl67acs78rrueanm198